IMBRUVICA
Showing 1 - 25 of 146
Breast Tumors, Malignant Tumor of Breast Trial in Dallas (Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg)
Recruiting
- Breast Neoplasms
- Malignant Neoplasm of Breast
- Trastuzumab
- +3 more
-
Dallas, Texas10 sites incl TX, WA, VA, and NV
May 16, 2022
Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),
Active, not recruiting
- Head and Neck Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Ibrutinib 560mg PO daily (Imbruvica)
- +2 more
-
La Jolla, CaliforniaUCSD Moores Cancer Center
Jan 11, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Small Lymphocytic Lymphoma
- (no location specified)
Jul 19, 2023
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (Cirmtuzumab (2-16
Recruiting
- B-cell Chronic Lymphocytic Leukemia
- +3 more
- Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
- +5 more
-
Duarte, California
- +12 more
Jun 16, 2022
Diffuse Large B Cell Lymphoma Trial in Berlin (Ibrutinib and Bortezomib + R-CHOP)
Active, not recruiting
- Diffuse Large B Cell Lymphoma
- Ibrutinib and Bortezomib + R-CHOP
-
Berlin, GermanyCharité - Universitätsmedizin Berlin, Hematology, Oncology and T
Aug 10, 2022
Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)
Not yet recruiting
- Mantle Cell Lymphoma Refractory
- Ibrutinib
- +3 more
- (no location specified)
May 16, 2023
Glioblastoma Trial in Cleveland (Ibrutinib, Radiation, Temozolomide (TMZ))
Active, not recruiting
- Glioblastoma
- Ibrutinib
- +2 more
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 30, 2023
Recurrent Chronic Lymphoid Leukemia Trial in Boston (ACY-1215, Ibrutinib, Idelalisib)
Active, not recruiting
- Recurrent Chronic Lymphoid Leukemia
- ACY-1215
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 19, 2022
Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in
Active, not recruiting
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 20, 2023
Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)
Completed
- Waldenstrom's Macroglobulinemia
-
Boston, Massachusetts
- +1 more
Dec 5, 2022
CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)
Recruiting
- Central Nervous System B-Cell Non-Hodgkin Lymphoma
- +2 more
- Ibrutinib
- Nivolumab
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2022
Waldenstrom's Macroglobulinemia Trial in Boston (Ulocuplumab, Ibrutinib)
Active, not recruiting
- Waldenstrom's Macroglobulinemia
-
Boston, MassachusettsDana Farber Cancer Institute
Jun 20, 2022
Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Ibrutinib
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
May 13, 2022
CNS Lymphoma Trial in Petah Tikva (Imbruvica)
Recruiting
- Central Nervous System Lymphoma
- Imbruvica
-
Petah Tikva, IsraelHematology Institute
May 9, 2022
Chronic Lymphocytic Leukemia Trial in Milano (Ibrutinib and obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib and obinutuzumab
-
Milano, MI, ItalyStrategic Research Program on CLL
Apr 2, 2022
Colon Cancer, Colorectal Cancer, Colorectal Carcinoma Trial in Tampa (Pembrolizumab, Ibrutinib)
Completed
- Colon Cancer
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jun 1, 2022
Waldenstrom Macroglobulinemia, MYD88 Gene Mutation Trial in Boston (IBRUTINIB, Venetoclax)
Active, not recruiting
- Waldenstrom Macroglobulinemia
- MYD88 Gene Mutation
-
Boston, Massachusetts
- +1 more
Apr 1, 2022
Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI (Duvelisib, Ibrutinib)
Terminated
- Small Lymphocytic Leukemia (SLL)
- Chronic Lymphocytic Leukemia (CLL)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 15, 2022
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,
Active, not recruiting
- Metastatic Melanoma
- +6 more
- Ibrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 13, 2023
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
-
Monterey, California
- +4 more
Aug 29, 2022
Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the NHLBI (Ibrutinib, Fludarabine)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Mar 1, 2022